Skip to the content
 

Monash Centre for Inflammatory Diseases

Associate Professor William Sievert

William Sievert is Director, Gastrointestinal and Liver Unit, Southern Health, which incorporates two large teaching hospitals, the Monash Medical Centre and Dandenong Hospital.  He is also a tenured associate professor in the Faculty of Medicine, Nursing and Health Sciences at Monash University.  Associate Professor Sievert has a long-term interest in liver disease and directs an active clinical research unit comprising physician-scientists, clinical research nurses and research students. The Clinical Research Unit has been continuously active over ten years and regularly contributes to international trials of new antiviral agents for hepatitis B and C in addition to developing and leading national investigator-initiated studies.  He also directs a basic research laboratory investigating mechanisms of inflammatory liver injury and hepatic fibrogenesis, with a translational focus on identification and development of potential hepatic antifibrotic agents. Associate Professor Sievert has been active in medical education including the development of new undergraduate and graduate medical curricula at Monash University.

Publications 2002 - 2008

  1. Marcellin P, Chang TT, Lim SG, Sievert W, Tong M, Arterburn S, Borroto-Esoda K, Frederick D, Rousseau F. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.  Hepatology. 2008 Sep;48(3):750-8.
  2. Lim SG, Marcellin P, Tassopoulos N, Hadziyannis S, Chang TT, Tong M, Sievert W, Hu P, Arterburn S, Brosgart CL; International Investigator Groups for Studies 437 and 438.  Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B.  Aliment Pharmacol Ther. 2007 Nov 15;26(10):1419-28.
  3. Chan HL, Heathcote EJ, Marcellin P, Lai CL, Cho M, Moon YM, Chao YC, Myers RP, Minuk GY, Jeffers L, Sievert W, Bzowej N, Harb G, Kaiser R, Qiao XJ, Brown NA; 018 Study Group.   Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med. 2007 Dec 4;147(11):745-54. Epub 2007 Oct 1. Summary for patients in: Ann Intern Med. 2007 Dec 4;147(11):I16.
  4. Lim S, Marcellin P, Tassopoulos N, Hadziyannis S, Chang T, Tong M, Sievert W, Hu P, Arterburn S, Brosgart C; ON BEHALF OF THE INTERNATIONAL INVESTIGATOR GROUPS FOR STUDIES 437 AND 438.  Effects of adefovir dipivoxil therapy in asian and caucasian patients with chronic hepatitis B. Aliment Pharmacol Ther. 2007 Sep 14.
  5. McNally S, Temple-Smith M, Sievert W, Pitts MK. Now, later or never? Challenges associated with hepatitis C treatment. Aust N Z J Public Health. 2006 Oct;30(5):422-7.
  6. Alexander S, Korman MG, Sievert W.  Cyanoacrylate in the treatment of gastric varices complicated by multiple pulmonary emboli. Intern Med J. 2006 Jul;36(7):462-5.
  7. Patella S, Phillips DJ, Tchongue J, de Kretser DM, Sievert W.  Follistatin attenuates early liver fibrosis: effects on hepatic stellate cell activation and hepatocyte apoptosis. Am J Physiol Gastrointest Liver Physiol. 2006 Jan;290(1):G137-44. Epub 2005 Aug 25.
  8. Butler JR, Pianko S, Korda RJ, Nguyen S, Gow PJ, Roberts SK, Strasser SI, Sievert W.  The direct cost of managing patients with chronic hepatitis B infection in Australia. J Clin Gastroenterol. 2004 Nov-Dec;38(10 Suppl 3):S187-92.
  9. Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, Plym M, Pokornowski K, Yu CF, Angus P, Ayres A, Bartholomeusz A, Sievert W, Thompson G, Warner N, Locarnini S, Colonno RJ.  Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother. 2004 Sep;48(9):3498-507.
  10. Dev A, Sundararajan V, Sievert W. Ethnic and cultural determinants influence risk assessment for hepatitis C acquisition. J Gastroenterol Hepatol. 2004 Jul;19(7):792-8.
  11. Sievert W.  Antiviral therapy for chronic hepatitis C. Aust Fam Physician. 2003 Oct;32(10):826-32.
  12. Sievert W, Batey R, Mollison L, Pianko S, McDonald J, Marinos G, Reed W, Warner S, Bowden S, De Solom R, Bhathal P; AusHep Investigators.  Induction interferon and ribavirin for re-treatment of chronic hepatitis C patients unresponsive to interferon alone. Aliment Pharmacol Ther. 2003 May 1;17(9):1197-204.
  13. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL; Adefovir Dipivoxil 437 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003 Feb 27;348(9):808-16.
  14. Dev AT, McCaw R, Sundararajan V, Bowden S, Sievert W.  Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome. Hepatology. 2002 Nov;36(5):1259-65.
  15. Danta M, Dore GJ, Hennessy L, Li Y, Vickers CR, Harley H, Ngu M, Reed W, Desmond PV, Sievert W, Farrell GC, Kaldor JM, Batey RG. Factors associated with severity of hepatic fibrosis in people with chronic hepatitis C infection. Med J Aust. 2002 Sep 2;177(5):240-5.
  16. Nagappan R, Parkin G, Simpson I, Sievert W. Fulminant hepatic failure from herpes simplex in pregnancy. Med J Aust. 2002 Jun 17;176(12):595-6.
  17. Sievert W, Pianko S, Warner S, Bowden S, Simpson I, Bowden D, Locarnini S. Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy: a long term follow-up study in hepatitis C-infected patients with beta thalassemia major. Am J Gastroenterol. 2002 Apr;97(4):982-7.
  18. Sievert W.  Management issues in chronic viral hepatitis: hepatitis C.  J Gastroenterol Hepatol. 2002 Apr;17(4):415-22. Review.
  19. Dev A, Sievert W.  A survey of Australian general practice management of hepatitis C-infected patients from non-English-speaking backgrounds. J Gastroenterol Hepatol. 2002 Mar;17(3):295-300.
  20. Kelly HA, Maskill WJ, Sievert W, Bowden DS. Serum alanine aminotransferase levels and the detection of hepatitis C virus (HCV) in chronic HCV infections. Med J Aust. 2002 Feb 4;176(3):139.